South America Dipeptide Peptidase 4 (DDP-4) Inhibitors Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

South America Dipeptide Peptidase 4 (DDP-4) Inhibitors Market Trends and Insights

Rising Type 2 Diabetes Prevalence

The International Diabetes Federation estimated that 35 million adults lived with diabetes across South and Central America in 2024, and 30.4%, or 10.7 million people, remained undiagnosed.^{[1]International Diabetes Federation, “IDF Diabetes Atlas, 11th Edition,” IDF Diabetes Atlas, diabetesatlas.org.} Brazil recorded a clear increase in adult diabetes prevalence, from 5.5% in 2006 to 12.9% in 2024.^{[2]Sociedade Brasileira de Diabetes, “Obesidade e Diabetes Tipo 2 Crescem no Brasil, Mostra Pesquisa,” Sociedade Brasileira de Diabetes, profissional.diabetes.org.br.} The same national evidence linked the disease burden with excess weight affecting 60% of Brazilian adults. The South American DPP-4 inhibitors market, therefore, has a larger pool of patients who may need continuing glucose-lowering treatment after diagnosis. Primary-care screening in lower-income urban areas can bring people with episodic healthcare contact into treatment pathways. Affordable oral therapies can be important when those patients begin treatment outside specialist settings.

Growing Need for Weight-Neutral Oral Therapies

DPP-4 inhibitors provide a weight-neutral oral option, unlike sulfonylureas and insulin regimens that may create a risk of weight gain. This characteristic is important where obesity and type 2 diabetes commonly occur together and where treatment adherence can be affected by the burden of injectable care. Brazil’s 2025 clinical guidance retained DPP-4 inhibitors as treatment options for suitable patients with HbA1c below 7.5% who cannot access or tolerate GLP-1 receptor agonists or SGLT2 inhibitors. This guidance preserves a defined role for oral treatment within the South American DPP-4 inhibitors market, rather than treating the class as interchangeable with injectable therapies. Higher prices for injectable medicines can lead physicians and patients to consider weight-neutral oral alternatives. Generic availability can make that choice more accessible in price-sensitive settings and can preserve DPP-4 use while branded products face erosion.

Expansion of Combination Therapy Regimens

Clinical guidance in Brazil supports dual therapy at diagnosis when HbA1c is 7.5% or higher. This approach broadens the role of DPP-4 inhibitors beyond use as a single medicine for patients who present later in disease progression. Fixed-dose products combining a DPP-4 inhibitor with metformin can reduce pill burden and make adherence simpler for people managing multiple medicines. Generic combinations can also fit public procurement budgets more easily than separate branded products. DPP-4 and SGLT2 combinations are appearing in Brazilian tertiary hospital formularies and package more than glucose control within a single oral regimen. Their cardiovascular and renal treatment relevance can help maintain DPP-4 prescribing where standalone injectable alternatives are not appropriate or feasible.

Renal-Disease-Linked Preference for Linagliptin

More diagnosis and treatment of diabetes can increase prescription demand in Brazil, Colombia, and Peru, especially among patients who previously had no regular contact with diabetes services. The International Diabetes Federation expects the number of adults with diabetes in South and Central America to reach 52 million by 2050. Linagliptin does not require dose adjustment across stages of chronic kidney disease because it is primarily eliminated through biliary pathways. A 2025 clinical review reported lower hypoglycemia risk for DPP-4 inhibitors, especially linagliptin, than for sulfonylureas in people with type 2 diabetes and chronic kidney disease.^{[3]Ravindra K. Vart et al., “Choosing Oral Antihyperglycaemic Drugs in People Living with Type 2 Diabetes and Severe Chronic Kidney Disease,” Journal of Internal Medicine, onlinelibrary.wiley.com.} A 2024 study also found financial benefits from renal dose-adjusted DPP-4 prescribing for patients with diabetes and chronic kidney disease. Local manufacturing, established bioequivalence certification, and decentralized generic tenders can help qualified suppliers serve this demand in Brazil and Argentina.

Competition from GLP-1 Receptor Agonists and SGLT2 Inhibitors

The South American DPP-4 inhibitors market faces increased competition from GLP-1 receptor agonists and SGLT2 inhibitors. Lower-cost GLP-1 products can draw patients with obesity, high HbA1c levels, or cardiovascular risk toward injectable care. Brazil approved domestic production for liraglutide-based products in December 2024. Injectable therapies still require cold-chain handling and patient training. These requirements limit access beyond larger urban areas and specialist services. Oral DPP-4 therapies retain an operational advantage for primary care and rural use.

Reimbursement and Out-of-Pocket Affordability Constraints

Fragmented reimbursement limits the ability of branded DPP-4 products to expand across South America. Brazil’s public formulary has focused on metformin and sulfonylureas, leaving many DPP-4 purchases in private co-payment channels. Price sensitivity is especially relevant in Argentina, Colombia, and Peru. Separate registration and bioequivalence requirements in Brazil and Argentina add cost to multi-country product management. Patent expiry can also reduce branded value quickly when generic products become available. Merck’s 2024 annual report disclosed exclusivity for Januvia and Janumet through May 2026, illustrating the value exposure facing established oral diabetes brands.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Drug Type: Saxagliptin Leads While Linagliptin Gains Clinical Relevance

Saxagliptin held 45.32% of value in 2025, making it the largest molecule in the South American DPP-4 inhibitors market. Its position was built through more than a decade of physician familiarity, earlier category-leading clinical trial data, and formulary placement in Brazil and Argentina. Branded Onglyza and a growing generic supply base support continuing use across hospital and private care settings. Generic supply helps sustain patient volumes even when branded unit prices decline. Linagliptin is forecasted to expand at a 5.22% CAGR through 2031 because it offers a distinct option for patients who also have chronic kidney disease.

The South American DPP-4 inhibitors market for linagliptin is supported by its biliary elimination, which removes the need for renal dose adjustments across chronic kidney disease stages. Clinical evidence associates linagliptin with a lower risk of hypoglycemia than sulfonylureas in patients with diabetes and chronic kidney disease. Vildagliptin retains a credible Brazilian private-care position through branded products and generic combinations with metformin, while alogliptin remains in selected institutional contracts.

By Medication Type: Generic Products Grow as Branded Products Retain Value

Branded medications accounted for 71.42% of value in 2025, while generic medications are forecasted to grow at a 6.24% CAGR through 2031. Originators retain value through established hospital formulary relationships, specialist familiarity, and private insurance preferences in Brazil and Argentina. The South American DPP-4 inhibitors market is nevertheless shifting toward bioequivalent alternatives through Brazilian public tenders and provincial procurement in Argentina. Generic products can lower acquisition costs for health systems and make established molecules more attainable for self-paying patients. This shift supports treatment volume even as it compresses branded pricing.

The South American DPP-4 inhibitors market size is also shaped by which suppliers can satisfy country-specific bioequivalence and registration standards. ANVISA requirements can favor manufacturers with established evidence packages, local regulatory capabilities, and consistent supply arrangements. The resulting process can reduce the number of companies able to compete effectively for public tenders.

By Distribution Channel: Hospitals Remain Central as Online Access Expands

Hospital pharmacies accounted for 48.52% of the distribution value in 2025 and remained the largest channel in the South American DPP-4 inhibitors market. State procurement contracts and accredited hospital networks underpin this position in Brazil. Hospital purchasing also establishes price benchmarks that can influence the wider medicines supply chain. Retail pharmacies serve insured and self-paying urban patients in Brazil, Argentina, and Chile, where pharmacy chains provide direct dispensing outside institutional procurement. Together, hospital and retail settings provide established channels for patients who need uninterrupted oral diabetes therapy.

Online pharmacies are expected to grow at 5.63% CAGR through 2031. Oral DPP-4 tablets are suited to ordinary e-commerce fulfillment because they are shelf-stable and do not need cold-chain delivery. This provides an operational advantage over GLP-1 pens, which need temperature-controlled handling and more complex last-mile delivery. Digital access can make repeat purchases easier for established chronic-condition patients, particularly where pharmacy chains have widened online ordering. The digital channel complements hospital procurement and physical retail access rather than replacing either source of supply.

Geography Analysis

Brazil held 56.72% of the South American DPP-4 inhibitors market share in 2025, giving it the region’s largest country position. The country combines public procurement through the Unified Health System, broad private formulary access, and a developed retail pharmacy network. These channels support dispensing across large urban populations and institutional care settings. Adult diabetes prevalence rose from 5.5% in 2006 to 12.9% in 2024. Brazil’s 2025 clinical guidance continued to recognize DPP-4 inhibitors as oral options for suitable people without high cardiovascular risk.

Argentina is projected to grow at a 7.16% CAGR through 2031, the highest rate among the countries covered. The International Diabetes Federation recorded 4.3 million adults with diabetes in Argentina in 2024 and an age-standardized diabetes prevalence of 14%. Argentina’s 2025 clinical guidance retained DPP-4 inhibitors within the oral treatment algorithm. Separate stability-testing and registration requirements can increase costs for imported finished-dose products. They can also create openings for generic manufacturers that develop locally adapted dossiers.

Colombia, Chile, Peru, and the rest of South America represented the remaining value in 2025. Colombia’s wider health coverage can improve diabetes diagnosis and the use of oral antidiabetics in primary care. Chile’s regulatory setting can support generic entry and a competitive price environment. Peru and smaller countries remain constrained by healthcare infrastructure gaps, while PAHO supports regional diabetes screening and early diagnosis.